Connecting Molecules to Medicine™
See What Makes Nexus Pharmaceuticals Different
Through our commitment to innovative R&D, Nexus Pharmaceuticals identifies off-patent and difficult to formulate molecules that can be developed, improved upon, and commercialized to advance industry standards and deliver on critical medical needs.
Is your pharmaceutical manufacturer a certified diverse supplier?
New State-of-the-Art Manufacturing Facility located in Pleasant Prairie, WI
Commitment to Quality
From Molecules to Medicine
State-of-the-Art Sterile Injectable Manufacturing Facility
Located in Pleasant Prairie, Wisconsin, we broke ground in 2019 to build Project Tomorrow, a state-of-the-art sterile injectable manufacturing facility to support the production and supply of injectable drugs in various therapeutic areas including anesthesiology, oncology, cardiology, and neurology. We plan to invest $250 million over the next ten years and create over 400 jobs in total.
News
Nexus Pharmaceuticals Inc. Receives FDA Approval of Erythromycin
LINCOLNSHIRE, Ill.–(BUSINESS WIRE)–Nexus Pharmaceuticals Inc. announced that it has received US Food and Drug Administration (FDA) approval for Erythromycin Lactobionate for Injection, USP in 500mg/vial in single-dose vials. It is an AP-rated generic to ERYTHROCIN™¥.
Our Response to “Our Drug Supply Is Sick. How Can We Fix It?”
I am writing with regards to the Opinion piece titled, “Our Drug Supply Is Sick. How Can We Fix It?” (Sept. 18, 2021). As the writer clearly highlights, the U.S. generic pharmaceutical industry is facing a crisis. Our company, Nexus Pharmaceuticals, Inc., is leading...
Nexus Pharmaceuticals Receives Patent for EMERPHED®
Nexus Pharmaceuticals, Inc., a U.S.-based healthcare company and domestic pharmaceutical manufacturer, has received a patent covering applications of EMERPHED® Ready-To-Use Ephedrine Sulfate Injection, the first FDA-approved premixed ephedrine in a ready-to-use 50 mg/10 mL vial. The United States Patent and Trademark Office (USPTO) issued the patent, U.S. Patent No. 11,090,278, on August 17, 2021.
Find out what we’re about
Discover more about Nexus Pharmaceuticals and get in touch today!
Lincolnshire, IL 60069 United States